Evaluation of the Efficiency of N-terminal Pro-B-type Natriuretic Peptide for Diagnosis of Acute Myocardial Infarction


Background: Cardiac diseases are one of the major causes of death worldwide with increasing incidence rate per year, particularly in developing countries such as Sudan owing to urbanization and changing lifestyle. Myocardial infarction is a consequence of the imbalance between the heart blood supply and the required heart cell; this disorder leads to necrosis of myocardium and may cause death. It could be diagnosed by at least two of the following criteria: chest pain, electrocardiography (ECG) elevation, and levels on cardiac biomarkers. This study aimed to evaluate the efficiency of N-terminal pro-B-type natriuretic peptide (NTproBNP) for the diagnosis of acute myocardial infarction (AMI).

 Methods: This analytical case–control hospital-based study was conducted on a total of 70 individuals, of which 40 participants were suspected of or diagnosed with AMI, while 30 healthy subjects  were included as a control group. Three ml of venous blood were collected in lithium heparin containers. Troponin I (TnI) as a cardiac biomarker was measured by TOSOH AIA-360, while the NTproBNP level was detected using I-Chroma II. Personal and clinical data were collected directly from each participant using a predesigned questionnaire.

Results: A significant increase in the TnI level (mean: 13.13 ± 18.9 ng/ml) and NTproBNP (mean: 5756.5 ± 8378.2 pg/mL) in AMI patients were detected when compared with control mean (0.02 ± 0.00 ng/ml and 57.8 ± 42.32 pg/mL, respectively).

Conclusions: NTproBNP gave a high sensitivity (87.5%), specificity (100%), positive predictive value (100%), and negative predictive value (85.7%) in the diagnosis of AMI when compared with another cardiac biomarker such as TnI.

Keywords: acute myocardial infarction, NTproBNP, troponin I, Medani Heart Center, Sudan

[1] Danish, M. I. (2012). Short Textbook of Medical Diagnosis and Management. Medtech.
[2] Gary, A. T. and Kevin, T. P. (2015). Anatomy and Physiology (9th ed.). Netherlands: Elsevier Health Sciences.
[3] Ambrose, J. A. and Singh, M. (2015). Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Reports, vol. 14, no. 7, p. 08. DOI: 10.12703/P7-08.
[4] Yang, Z. and Zhou, D. (2006). Cardiac marker and their point of care testing for diagnosis of acute myocardial infarction Clinical Biochemistry, vol. 39, no. 8, pp. 771–780.
[5] Omer, A., Mohemed, E., Abdulrahman, A., et al. (2016) Studying of heart disease prevalence, distribution and co-factors in Sudanese population. International Journal of Research in Medical Sciences, vol. 4, no. 1, p. 206. DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20160032.
[6] Lee, G. and Andrew, S. (2012). Goldman’s Cecil Medicine (24th ed.). Philadelphia, PA: Elsevier Saunders.
[7] Chatzizisis, Y. S., Saravakos, P., Boufidou, A., et al (2010). Acute myocardial infarction manifested with headache. Open Cardiovascular Medicine Journal, vol. 16, no. 4, pp. 148–150. DOI: 10.2174/1874192401004010148.
[8] Skelly, A. C., Hashimoto, R., Buckley, D. I., et al. (2016). Non-invasive testing for coronary artery disease [Internet] (Comparative Effectiveness Reviews, No. 171.) . Rockville (MD): Agency for Healthcare Research and Quality (US). Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK361148
[9] Christenson, E. and Christenson, R. H. (2013). The role of cardiac biomarkers in the diagnosis and management of patients presenting with suspected acute coronary syndrome. Annals of Laboratory Medicine, vol. 33, no. 5, pp. 309–318. DOI: 10.3343/alm.2013.33.5.309.
[10] Mythili, S. and Malathi, N. (2015). Diagnostic markers of acute myocardial infarction. Biomedical Reports, vol. 3, no. 6, pp. 743–748. DOI: 10.3892/br.2015.500.
[11] Korff, S., Katus, H. A., and Giannitsis, E. (2006). Differential diagnosis of elevated troponins. Heart, vol. 92, no. 7, pp. 987–993. DOI: 10.1136/hrt.2005.071282.
[12] Expert Group on Biomarkers. (2015). Biomarkers in cardiology - part 2: in coronary heart disease, valve disease and special situations. Arquivos Brasileiros de Cardiologia, vol. 104, no. 5, pp. 337–346. DOI: 10.5935/abc.20150061.
[13] Scott, W. D. and Meg, S. (2008). Cardiac troponins. Journal of Veterinary Emergency and Critical Care, vol. 18, no. 3, pp. 235–245. DOI: 10.1111/j.1476-4431.2008.00307.X.
[14] Regan, B., O'Kennedy, R., and Collins, D. (2018). Point-of-care compatibility of ultra-sensitive detection techniques for the cardiac biomarker troponin I – challenges and potential value. Biosensors, vol. 8, no. 4, p. 114. DOI: 10.3390/bios8040114.
[15] Korff, S., Katus, H. A., and Giannitsis, E. (2006). Differential diagnosis of elevated troponins. Heart, vol. 92, no. 7, pp. 987–993. DOI: 10.1136/hrt.2005.071282.
[16] Michael, L. B., Edwart, P. F., and Larry, E. S. (2013). Clinical Chemistry Principles, Techniques, and Correlations (7th ed.). Burlington, MA: Jones & Bartlett Learning.
[17] Wendy, A. and Jean, B. (2007). Clinical Chemistry A Laboratory Perspective (1st ed.). Philadelphia, PA: F. A. Davis Company.
[18] Ichiki, T., Huntley, B. K., and Burnett, J. C., Jr. (2013). BNP molecular forms and processing by the cardiac serine protease corin. Advances in Clinical Chemistry, vol. 61, pp. 1–31. DOI: 10.1016/b978-0-12-407680-8.00001-4.
[19] Ahmed, Y. M. M. (2017). Estimation of Serum Ferritin Level among Myocardial Infarction Patients attending Wad Madani Heart Center, Gezira State, Sudan (2016–2017) (Master Dissertation, University of Gezira, Sudan).
[20] Ahmed, M. H., Awadalla, H., Elmadhoun, W. M., et al. (2017) Prevalence and risk factors for acute coronary syndrome among Sudanese individuals with diabetes: a population-based study. Cardiology Research, vol. 8, no. 5, p. 184.
[21] Bahaaeldin, A. E., Alsafi, A. A., and Mohammed, A. A. (2016). Correlation of smoking and myocardial infarction among Sudanese male patients above 40 years of age. Polish Journal of Radiology, vol. 81, pp. 138–140. DOI: 10.12659/PJR.894068.
[22] Abdallah, M. A. A. (2018). Red Cell Distribution Width As a Prognostic Marker for Patients with Myocardial Infarction, Wadmadani Heart Centre, Gezira State, Sudan (Master Dissertation, University of Gezir, Sudan).
[23] Kristensen, S. L., Mogensen, U. M., Jhund, P. S., et al. (2019). N-terminal pro-B-type natriuretic peptide levels for risk prediction in patients with heart failure and preserved ejection fraction according to atrial fibrillation status. Circulation: Heart Failure, vol. 12, no. 3, e005766. DOI: 10.1161/CIRCHEARTFAILURE.118.005766.
[24] Navaid, I., Wentworth, B., Choudhary, R., et al. (2012). Cardiac biomarkers: new tools for heart failure management. Cardiovascular Diagnosis and Therapy, vol. 2, no. 2, pp. 147–164. DOI: 10.3978/j.issn.2223-3652.2012.6.03.
[25] Dimiati, H., Wahab, A. S., Juffrie, M., et al. (2019) Study of NTproBNP and Hs-Troponin I biomarkers for early detection of children's heart function of proteinenergy malnutrition. Pediatric Reports, vol. 11, no. 2, p. 7997. DOI: 10.4081/pr.2019.7997.